H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $27 from $26 and keeps a Buy rating on the shares after the company announced its 2026 milestones.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook
- Cullinan Therapeutics price target raised to $30 from $28 at Morgan Stanley
- Cullinan Therapeutics provides corporate update, anticipated 2026 milestones
- Cullinan Therapeutics price target raised to $33 from $22 at Clear Street
- Cullinan Therapeutics price target raised to $34 from $25 at Wedbush